Media coverage about Cellectis (NASDAQ:CLLS) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellectis earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.9336143379141 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Cellectis (NASDAQ:CLLS) opened at $32.43 on Friday. The firm has a market cap of $1,165.15, a PE ratio of -13.46 and a beta of 2.07. Cellectis has a 12 month low of $19.76 and a 12 month high of $35.07.
CLLS has been the topic of a number of recent analyst reports. Jefferies Group restated a “buy” rating and issued a $47.00 target price on shares of Cellectis in a research note on Sunday, October 29th. Oppenheimer restated an “outperform” rating and issued a $40.00 target price on shares of Cellectis in a research note on Thursday, December 28th. BidaskClub lowered shares of Cellectis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. ValuEngine lowered shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research lowered shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $39.29.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://transcriptdaily.com/2018/02/25/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-cellectis-clls-stock-price.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.